This document is an excerpt from the EUR-Lex website
Document 62020TN0248
Case T-248/20: Action brought on 5 May 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXYMLA)
Case T-248/20: Action brought on 5 May 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXYMLA)
Case T-248/20: Action brought on 5 May 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXYMLA)
OJ C 209, 22.6.2020, p. 38–39
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
22.6.2020 |
EN |
Official Journal of the European Union |
C 209/38 |
Action brought on 5 May 2020 — Stada Arzneimittel v EUIPO — Pfizer (RUXYMLA)
(Case T-248/20)
(2020/C 209/49)
Language in which the application was lodged: German
Parties
Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: Pfizer Inc. (New York, New York, United States)
Details of the proceedings before EUIPO
Applicant for the trade mark at issue: Applicant
Trade mark at issue: Application for EU word mark RUXYMLA — Application for registration No 17 865 739
Procedure before EUIPO: Opposition proceedings
Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 13 February 2020 in Case R 1878/2019-4
Form of order sought
The applicant claims that the Court should:
|
— |
annul the contested decision; |
|
— |
order EUIPO to pay the costs of the proceedings, including the costs of the appeal proceedings. |
Plea in law
|
— |
Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |